Trial Profile
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients With Lower Risk Myelodysplastic Syndrome (MDS) With Low Red Blood Cell (RBC) Transfusion Burden (LTB)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Roxadustat (Primary)
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Acronyms MATTERHORN
- Sponsors FibroGen
- 04 Feb 2024 This trial has been discontinued in Italy.
- 12 Dec 2023 Results of final 28-week interim analysis of the double-blind stage (data cutoff: April 24, 2023,n=140) pts presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 09 Dec 2023 According to a FibroGen media release, The oral presentation was selected for the "2024 Highlights of ASH".